×
Zoetis Revenue 2011-2024 | ZTS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Zoetis revenue for the twelve months ending June 30, 2024 was
$8.915B
, a
8.43% increase
year-over-year.
Zoetis annual revenue for 2023 was
$8.544B
, a
5.74% increase
from 2022.
Zoetis annual revenue for 2022 was
$8.08B
, a
3.91% increase
from 2021.
Zoetis annual revenue for 2021 was
$7.776B
, a
16.49% increase
from 2020.
View More
Zoetis Revenue 2011-2024 | ZTS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Zoetis annual revenue for 2023 was
$8.544B
, a
5.74% increase
from 2022.
Zoetis annual revenue for 2022 was
$8.08B
, a
3.91% increase
from 2021.
Zoetis annual revenue for 2021 was
$7.776B
, a
16.49% increase
from 2020.
Related Stocks
Company Name
Market
Cap
Takeda Pharmaceutical (TAK)
$47.3B
Merck (MKGAF)
$23.7B
Astellas Pharma (ALPMY)
$21.5B
Summit Therapeutics (SMMT)
$19B
Sandoz Group AG (SDZNY)
$17.5B
United Therapeutics (UTHR)
$15.4B
Shionogi (SGIOY)
$13.3B
Neurocrine Biosciences (NBIX)
$12.4B
Catalent (CTLT)
$11B
Orion OYJ (ORINY)
$7.4B
Revolution Medicines (RVMD)
$7.3B
Jazz Pharmaceuticals (JAZZ)
$6.9B
Ionis Pharmaceuticals (IONS)
$6.1B
Hikma Pharmaceuticals Plc (HKMPF)
$5.7B
Madrigal Pharmaceuticals (MDGL)
$5.1B
Crinetics Pharmaceuticals (CRNX)
$4.2B
Corcept Therapeutics (CORT)
$4.1B
Dyne Therapeutics (DYN)
$3.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
PTC Therapeutics (PTCT)
$2.7B
Arrowhead Pharmaceuticals (ARWR)
$2.5B
Catalyst Pharmaceuticals (CPRX)
$2.4B
Soleno Therapeutics (SLNO)
$2.1B
Recursion Pharmaceuticals (RXRX)
$1.9B
Centessa Pharmaceuticals (CNTA)
$1.8B
Xencor (XNCR)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Harrow (HROW)
$1.5B
Cassava Sciences (SAVA)
$1.5B
Ardelyx (ARDX)
$1.4B